ArticleDiscover oncology2025
Single-cell transcriptomic analysis reveals the heterogeneity and functional characteristics of macrophage subpopulations in colon cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-Omics Analysis IdentifiedInternational journal of molecular sciences · 2026Article
- Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression.Oncoscience · 2026Review
- Cell competition within breast tumor microenvironment: emerging role of cancer stem cells and immune cells in tumor progression and therapeutic implications.Frontiers in oncology · 2026Review
- Peripheral blood cells and immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study with pharmacovigilance and single-cell analysis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColon cancer remains one of the leading causes of cancer-related mortality globally. Tumor-associated macrophages (TAMs) are key contributors to tumor progression within the tumor microenvironment (TME). However, the role of secreted phosphoprotein 1 (SPP1), a critical regulator of macrophage-tumor interactions, in specific macrophage subsets in colon cancer remains unclear.
methodsWe performed single-cell RNA sequencing (scRNA-seq) on tumor and adjacent normal tissues from three colon cancer patients. A comprehensive analysis integrating pseudotime trajectory, transcription factor network, cell-cell communication, and in silico SPP1 knockout modeling was conducted to characterize macrophage heterogeneity and function.
resultsFive macrophage subtypes were identified. Among them, the Macrophages_SPP1 was significantly enriched in tumors and exhibited enhanced glycolytic metabolism, lysosomal activity, angiogenesis, and immunosuppression functions. This subtype showed increased interactions with fibroblasts, particularly via FTL-SCARA5 and FTH1-SCARA5 ligand-receptor pairs, implicating roles in stromal remodeling. In silico SPP1 knockout identified 93 stable responsive genes enriched in MHC class II-related and immune regulatory pathways, highlighting the role of SPP1 in shaping an immunosuppressive TME.
conclusionsThe Macrophages_SPP1 subtype may contribute to colon cancer progression through metabolic reprogramming and stromal interactions, suggesting that SPP1 and the FTL-SCARA5 axis could represent potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.